Intravenous Lidocaine for Postoperative Fatigue After Laparoscopic TAPP Inguinal Hernia Repair

NCT07612839 | Not Yet Recruiting

• 1 other identifier: 25-42
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective randomized controlled study aims to evaluate the effect of perioperative intravenous lidocaine infusion on postoperative fatigue syndrome in patients undergoing elective laparoscopic TAPP inguinal hernia repair. Participants will be randomly assigned to receive either intravenous lidocaine infusion or standard perioperative management without lidocaine. The primary objective is to assess postoperative fatigue and recovery quality. Secondary outcomes include postoperative pain, analgesic consumption, nausea-vomiting, mobilization time, and length of hospital stay.

Conditions

Postoperative Fatigue Syndrome; Inguinal Hernia Unilateral

Keywords

Intravenous Lidocaine; Postoperative Fatigue; Laparoscopic TAPP Repair; Postoperative Recovery

Outcome Measures

Primary Outcomes (1)

• Postoperative Fatigue Syndrome Score

  Assessment of postoperative fatigue syndrome and recovery quality using postoperative follow-up evaluations conducted on postoperative days 1, 3 and 5 after elective laparoscopic TAPP inguinal hernia repair.

  Postoperative days 1, 3, 5

Secondary Outcomes (3)

• Postoperative Pain Score

  Postoperative days 1, 3, and 5

• Opioid Consumption

  Within postoperative 24 hours

• Postoperative Nausea and Vomiting

  Within postoperative 24 hours

Study Arms (2)

Lidocaine Group

EXPERIMENTAL

Participants in this group will receive perioperative intravenous lidocaine infusion according to ideal body weight. A loading dose of 1.5 mg/kg lidocaine diluted in 50 or 100 mL normal saline will be administered over 10 minutes before surgery, followed by an infusion of 1.5 mg/kg/hour during surgery. If the operation exceeds 2 hours, the infusion will be discontinued. The duration of surgery will be recorded. Lidocaine infusion will be stopped immediately if signs suggestive of local anesthetic systemic toxicity or unexplained hemodynamic instability occur during surgery.

Drug: Lidocaine

Control Group

NO INTERVENTION

Participants in this group will receive standard perioperative care without intravenous lidocaine infusion during elective laparoscopic TAPP inguinal hernia repair.

Interventions

Lidocaine DRUG

Perioperative intravenous lidocaine infusion will be administered according to the study protocol in patients undergoing elective laparoscopic TAPP inguinal hernia repair.

Lidocaine Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult patients aged 18 years and older Patients scheduled for elective laparoscopic TAPP inguinal hernia repair under general anesthesia ASA physical status I-II Patients who provide written informed consent -

You may not qualify if:

• Moderate to severe hepatic dysfunction Low cardiac output or severe heart failure Severe cardiac conduction abnormalities or clinically significant arrhythmias Planned concomitant use of high-dose local anesthetics, including infiltration or regional block Advanced age or frailty Pregnancy or breastfeeding Known allergy or contraindication to lidocaine Refusal to participate in the study

Sponsors & Collaborators

• Hakan Emirkadı: lead

Study Sites (1)

University of Health Sciences Sultan Abdulhamid Han Training and Research Hospital

Istanbul, Istanbul, 34668, Turkey (Türkiye)

Location

MeSH Terms

Interventions

Lidocaine

Intervention Hierarchy (Ancestors)

Acetanilides; Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines

Central Study Contacts

Hakan Emirkadı, MD

CONTACT

+905322609367; hemirkadi@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Anesthesiology and Reanimation Specialist

Model Details: Participants will be randomly assigned to either the intravenous lidocaine group or the control group in a parallel-group design.

Study Record Dates

• First Submitted: May 21, 2026
• First Posted: May 29, 2026
• Study Start: June 5, 2026
• Primary Completion (Estimated): August 10, 2026
• Study Completion (Estimated): September 10, 2026
• Last Updated: May 29, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)